Laboratory of Influenza Virus Surveillance, Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Influenza Other Respir Viruses. 2013 Nov;7(6):1390-9. doi: 10.1111/irv.12132. Epub 2013 Jun 8.
BACKGROUND/OBJECTIVES: Japan has the highest frequency of neuraminidase (NA) inhibitor use against influenza in the world. Therefore, Japan could be at high risk of the emergence and spread of NA inhibitor-resistant viruses. The aim of this study was to monitor the emergence of NA inhibitor-resistant viruses and the possibility of human-to-human transmission during four influenza seasons in Japan.
To monitor antiviral-resistant A(H1N1)pdm09 viruses, we examined viruses isolated in four seasons from the 2008-2009 season through the 2011-2012 season in Japan by allelic discrimination, NA gene sequencing, and NA inhibitor susceptibility.
We found that 157 (1·3%) of 12 026 A(H1N1)pdm09 isolates possessed an H275Y substitution in the NA protein that confers about 400- and 140-fold decreased susceptibility to oseltamivir and peramivir, respectively, compared with 275H wild-type viruses. The detection rate of resistant viruses increased from 1·0% during the pandemic period to 2·0% during the post-pandemic period. The highest detection rate of the resistant viruses was found in patients who were 0-9 years old. Furthermore, among the cases with resistant viruses, the percentage of no known exposure to antiviral drugs increased from 16% during the pandemic period to 44% during the post-pandemic period, implying that suspected human-to-human transmission of the resistant viruses gradually increased in the post-pandemic period.
A(H1N1)pdm09 viruses resistant to oseltamivir and peramivir were sporadically detected in Japan, but they did not spread throughout the community. No viruses resistant to zanamivir and laninamivir were detected.
背景/目的:日本是世界上使用神经氨酸酶(NA)抑制剂治疗流感频率最高的国家。因此,日本可能面临着出现和传播 NA 抑制剂耐药病毒的高风险。本研究旨在监测日本四个流感季节中 NA 抑制剂耐药病毒的出现以及人际传播的可能性。
为了监测抗流感病毒药物耐药的 A(H1N1)pdm09 病毒,我们通过等位基因鉴别、NA 基因测序和 NA 抑制剂敏感性试验,检测了日本 2008-2009 年至 2011-2012 年四个季节分离的病毒。
我们发现,与野生型 275H 病毒相比,157 株(1.3%)A(H1N1)pdm09 分离株的 NA 蛋白中存在 H275Y 取代,对奥司他韦和帕拉米韦的敏感性分别降低了约 400 倍和 140 倍。耐药病毒的检出率从大流行期间的 1.0%增加到大流行后期的 2.0%。耐药病毒的最高检出率见于 0-9 岁的患者。此外,在耐药病毒的病例中,无已知抗病毒药物暴露史的比例从大流行期间的 16%增加到大流行后期的 44%,这表明耐药病毒的人际传播在大流行后期逐渐增加。
日本偶有发现对奥司他韦和帕拉米韦耐药的 A(H1N1)pdm09 病毒,但并未在社区中传播。未检测到对扎那米韦和拉尼米韦耐药的病毒。